乌干达HIV-1暴露婴儿早期与晚期卡介苗接种:随机对照试验研究方案
本研究为在乌干达三个卫生中心开展的个体随机对照试验,纳入2200名HIV-1暴露婴儿,比较出生后24小时内接种卡介苗与14周龄接种卡介苗的效果。共同主要结局为出生后前14周内的严重疾病,以及针对分枝杆菌和非分枝杆菌抗原产生肿瘤坏死因子、白细胞介素-1β、白细胞介素-6和干扰素-γ的情况。该试验旨在为HIV-1暴露婴儿卡介苗接种时机的选择提供依据。
要点
- 研究纳入2200名HIV-1暴露婴儿,随机比较出生后24小时内与14周龄接种卡介苗。
- 共同主要结局为前14周严重疾病及对分枝杆菌和非分枝杆菌抗原的细胞因子反应。
- 试验在乌干达三个卫生中心开展,结果可为HIV-1暴露婴儿卡介苗接种时机提供依据。
核心结论
- 该试验旨在比较HIV-1暴露婴儿出生时接种卡介苗与14周龄接种卡介苗的效果,结果可能为确定HIV-1暴露婴儿卡介苗接种的适当时机提供依据。
研究设计与样本
- 研究为个体随机对照试验,在乌干达三个卫生中心纳入2200名HIV-1暴露婴儿。
- 干预为出生后24小时内接种卡介苗,对照为14周龄时接种卡介苗。
主要发现
- 共同主要结局为出生后前14周内的严重疾病,以及针对分枝杆菌和非分枝杆菌抗原产生肿瘤坏死因子、白细胞介素-1β、白细胞介素-6和干扰素-γ的情况。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bacillus Calmette-Guérin (BCG) vaccination may have nonspecific effects, i.e., effects on childhood morbidity and mortality that go beyond its effect on the risk of childhood tuberculosis (TB). Though the available scientific literature is mostly from observational studies, and is fraught with controversy, BCG vaccination at birth may protect infants in high-mortality populations against serious infections other than TB. Yet, other studies indicate that giving BCG later in infancy may modify immune responses to non-TB antigens and potentially enhance immunity, potentially also against tuberculosis (TB). It is unclear whether BCG vaccination very early in life offers adequate protection against TB and other infections among HIV-1-exposed children because even those who remain uninfected with HIV-1 show signs of impaired immunocompetence early in infancy. This study will compare BCG vaccination at birth with BCG vaccination at 14 weeks of age in HIV-1-exposed infants. METHODS: This is an individually randomized controlled trial in 2200 HIV-1-exposed infants. The intervention is BCG vaccination within 24 h of birth while the comparator is BCG given at 14 weeks of age. The study co-primary outcomes are severe illness in the first 14 weeks of life, and production of tumor necrosis factor, interleukin (IL)-1β, IL-6 and interferon-γ in response to mycobacterial and nonmycobacterial antigens. The study is being conducted in three health centers in Uganda. DISCUSSION: A well-timed BCG vaccination could have important nonspecific effects in HIV-1-exposed infants. This trial could inform the development of appropriate timing of BCG vaccination for HIV-1-exposed infants. TRIAL REGISTRATION: ClinicalTrials.gov, identifier: NCT02606526 . Registered on 12 November 2015.
引用
- Nankabirwa V, Tumwine JK, Namugga O, et al. Early versus late BCG vaccination in HIV-1-exposed infants in Uganda: study protocol for a randomized controlled trial. Trials. 2017. PMID: 28359325. doi:10.1186/s13063-017-1881-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。